Leap Therapeutics (NASDAQ:LPTX) Stock Price Down 9.2%

Leap Therapeutics Inc (NASDAQ:LPTX) dropped 9.2% during mid-day trading on Monday . The stock traded as low as $1.99 and last traded at $2.08, approximately 852,641 shares changed hands during mid-day trading. An increase of 34% from the average daily volume of 638,576 shares. The stock had previously closed at $2.29.

LPTX has been the topic of several research reports. Zacks Investment Research lowered shares of Leap Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 17th. ValuEngine raised shares of Leap Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday.

The firm’s 50-day moving average is $1.93. The company has a current ratio of 2.77, a quick ratio of 2.77 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $51.93 million, a P/E ratio of -0.83 and a beta of 2.34.

Leap Therapeutics (NASDAQ:LPTX) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.06). Equities research analysts predict that Leap Therapeutics Inc will post -1.62 earnings per share for the current year.

An institutional investor recently raised its position in Leap Therapeutics stock. Deutsche Bank AG increased its position in shares of Leap Therapeutics Inc (NASDAQ:LPTX) by 45.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 124,338 shares of the company’s stock after acquiring an additional 39,000 shares during the period. Deutsche Bank AG owned approximately 0.58% of Leap Therapeutics worth $248,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Leap Therapeutics Company Profile (NASDAQ:LPTX)

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.

Recommended Story: Fibonacci Channel

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.